APT Pharmaceuticals is focused on the development of cyclosporine inhalation solution (CIS) for the prevention and treatment of chronic rejection in lung transplantation. The company has successfully enrolled a large, multi-center Phase III clinical trial evaluating the effect of CIS on chronic rejection. APT is preparing for study data and commercialization of the product in the US and Europe. The company has an experienced management team and has partnered with leaders in the field of life sciences investing..
Financials
| Date | Type | Amount | Investors | Valuation |
|---|---|---|---|---|
| 10/05/07 | Series A | 22M | Unknown | |
| 09/01/08 | Series B | 32.3M | Unknown |
People
Sue Barrowcliffe (Vice-President, Regulatory)
Charlie Johnson (CMO)
Joe Melvin (Vice-President, Finance)
Stephen Dilly (President/CEO)
Paul Sekhri (President/CEO)
View more details about all 16 people at APT Pharmaceuticals
News
Atlanta-based WebMD to lay off 14% of its workforce
December 11, 2012 8:16 pm
Atlanta-based WebMD, the largest source of medical information on the Web according to Comscore, will cut 250 jobs in the… Continue reading ⟩
Funding Daily: An Indian mafia don, his daughter, and some funding news
October 11, 2012 12:52 am
I struggled with inspiration for today’s theme, and did what any reasonable person stricken with writer’s block does. I went… Continue reading ⟩
Longitude Capital pools money for drugs
October 10, 2012 8:41 pm
Longitude Capital amassed $385 million to invest in drug development and health technology for its second fund, Longitude Venture Partners II.… Continue reading ⟩